Browse HSD17B10

Summary
SymbolHSD17B10
Namehydroxysteroid (17-beta) dehydrogenase 10
Aliases ERAB; MHBD; 17b-HSD10; ABAD; SDR5C1; MRPP2; CAMR; type 10 17b-HSD; type 10 17beta-hydroxysteroid dehydrogena ......
Chromosomal LocationXp11.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Mitochondrion
Domain PF00106 short chain dehydrogenase
Function

Mitochondrial dehydrogenase that catalyzes the beta-oxidation at position 17 of androgens and estrogens and has 3-alpha-hydroxysteroid dehydrogenase activity with androsterone (PubMed:9553139, PubMed:23042678, PubMed:12917011, PubMed:18996107, PubMed:25925575, PubMed:28888424). Catalyzes the third step in the beta-oxidation of fatty acids (PubMed:9553139, PubMed:12917011, PubMed:18996107, PubMed:25925575, PubMed:28888424). Carries out oxidative conversions of 7-alpha-OH and 7-beta-OH bile acids (PubMed:12917011). Also exhibits 20-beta-OH and 21-OH dehydrogenase activities with C21 steroids (PubMed:12917011). By interacting with intracellular amyloid-beta, it may contribute to the neuronal dysfunction associated with Alzheimer disease (AD) (PubMed:9338779). Essential for structural and functional integrity of mitochondria (PubMed:20077426). ; FUNCTION: In addition to mitochondrial dehydrogenase activity, moonlights as a component of mitochondrial ribonuclease P, a complex that cleaves tRNA molecules in their 5'-ends (PubMed:18984158, PubMed:24549042, PubMed:25925575, PubMed:26950678, PubMed:28888424). Together with HSD17B10/MRPP2, forms a subcomplex of the mitochondrial ribonuclease P, named MRPP1-MRPP2 subcomplex, which displays functions that are independent of the ribonuclease P activity (PubMed:23042678, PubMed:29040705). The MRPP1-MRPP2 subcomplex catalyzes the formation of N(1)-methylguanine and N(1)-methyladenine at position 9 (m1G9 and m1A9, respectively) in tRNAs; HSD17B10/MRPP2 acting as a non-catalytic subunit (PubMed:23042678, PubMed:25925575, PubMed:28888424). The MRPP1-MRPP2 subcomplex also acts as a tRNA maturation platform: following 5'-end cleavage by the mitochondrial ribonuclease P complex, the MRPP1-MRPP2 subcomplex enhances the efficiency of 3'-processing catalyzed by ELAC2, retains the tRNA product after ELAC2 processing and presents the nascent tRNA to the mitochondrial CCA tRNA nucleotidyltransferase TRNT1 enzyme (PubMed:29040705).

> Gene Ontology
 
Biological Process GO:0000959 mitochondrial RNA metabolic process
GO:0000963 mitochondrial RNA processing
GO:0001510 RNA methylation
GO:0006399 tRNA metabolic process
GO:0006400 tRNA modification
GO:0008033 tRNA processing
GO:0009081 branched-chain amino acid metabolic process
GO:0009083 branched-chain amino acid catabolic process
GO:0009451 RNA modification
GO:0016054 organic acid catabolic process
GO:0030488 tRNA methylation
GO:0032259 methylation
GO:0034470 ncRNA processing
GO:0043414 macromolecule methylation
GO:0044282 small molecule catabolic process
GO:0070525 tRNA threonylcarbamoyladenosine metabolic process
GO:0070900 mitochondrial tRNA modification
GO:0070901 mitochondrial tRNA methylation
GO:0090646 mitochondrial tRNA processing
GO:1900864 mitochondrial RNA modification
GO:1901565 organonitrogen compound catabolic process
Molecular Function GO:0003857 3-hydroxyacyl-CoA dehydrogenase activity
GO:0008709 cholate 7-alpha-dehydrogenase activity
GO:0016229 steroid dehydrogenase activity
GO:0016614 oxidoreductase activity, acting on CH-OH group of donors
GO:0016616 oxidoreductase activity, acting on the CH-OH group of donors, NAD or NADP as acceptor
GO:0030283 testosterone dehydrogenase [NAD(P)] activity
GO:0033764 steroid dehydrogenase activity, acting on the CH-OH group of donors, NAD or NADP as acceptor
GO:0047015 3-hydroxy-2-methylbutyryl-CoA dehydrogenase activity
Cellular Component GO:0005759 mitochondrial matrix
> KEGG and Reactome Pathway
 
KEGG hsa00280 Valine, leucine and isoleucine degradation
hsa01100 Metabolic pathways
Reactome R-HSA-70895: Branched-chain amino acid catabolism
R-HSA-74160: Gene Expression
R-HSA-1430728: Metabolism
R-HSA-71291: Metabolism of amino acids and derivatives
R-HSA-72312: rRNA processing
R-HSA-8868766: rRNA processing in the mitochondrion
R-HSA-6787450: tRNA modification in the mitochondrion
R-HSA-72306: tRNA processing
R-HSA-6785470: tRNA processing in the mitochondrion
Summary
SymbolHSD17B10
Namehydroxysteroid (17-beta) dehydrogenase 10
Aliases ERAB; MHBD; 17b-HSD10; ABAD; SDR5C1; MRPP2; CAMR; type 10 17b-HSD; type 10 17beta-hydroxysteroid dehydrogena ......
Chromosomal LocationXp11.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between HSD17B10 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 

There is no record.

Summary
SymbolHSD17B10
Namehydroxysteroid (17-beta) dehydrogenase 10
Aliases ERAB; MHBD; 17b-HSD10; ABAD; SDR5C1; MRPP2; CAMR; type 10 17b-HSD; type 10 17beta-hydroxysteroid dehydrogena ......
Chromosomal LocationXp11.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of HSD17B10 in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell NA/NS NA/NS
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell logFC: -1.83; FDR: 0.04110 Resistant to T cell-mediated killing
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR NA/NS NA/NS
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NS NA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NS NA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NS NA/NS
24476824shRNAmelanomaB16Primary screen NA/NS NA/NS
24476824shRNAmelanomaB16Secondary screen NA/NS NA/NS
Summary
SymbolHSD17B10
Namehydroxysteroid (17-beta) dehydrogenase 10
Aliases ERAB; MHBD; 17b-HSD10; ABAD; SDR5C1; MRPP2; CAMR; type 10 17b-HSD; type 10 17beta-hydroxysteroid dehydrogena ......
Chromosomal LocationXp11.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of HSD17B10 in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)14120.1430.603
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)650.2040.947
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)870.1020.963
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160.0050.988
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 59-0.0870.958
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470.1190.953
729033130MelanomaallAnti-PD-1 (nivolumab) 26230.0240.946
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 1511-0.0750.962
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 11120.1360.938
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 48-0.3270.876
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 28-0.4230.896
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 682300.0720.322
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of HSD17B10 in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 14177.107.10.452
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 103100101
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 4140001
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 277301.4-1.41
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 0140001
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 275901.7-1.71
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)21170001
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)860001
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)13110001
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160001
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590001
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470001
1329033130MelanomaallAnti-PD-1 (nivolumab) 38270001
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 22130001
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 16140001
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 11130001
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 610001
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 5120001
Summary
SymbolHSD17B10
Namehydroxysteroid (17-beta) dehydrogenase 10
Aliases ERAB; MHBD; 17b-HSD10; ABAD; SDR5C1; MRPP2; CAMR; type 10 17b-HSD; type 10 17beta-hydroxysteroid dehydrogena ......
Chromosomal LocationXp11.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of HSD17B10. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolHSD17B10
Namehydroxysteroid (17-beta) dehydrogenase 10
Aliases ERAB; MHBD; 17b-HSD10; ABAD; SDR5C1; MRPP2; CAMR; type 10 17b-HSD; type 10 17beta-hydroxysteroid dehydrogena ......
Chromosomal LocationXp11.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of HSD17B10. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by HSD17B10.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolHSD17B10
Namehydroxysteroid (17-beta) dehydrogenase 10
Aliases ERAB; MHBD; 17b-HSD10; ABAD; SDR5C1; MRPP2; CAMR; type 10 17b-HSD; type 10 17beta-hydroxysteroid dehydrogena ......
Chromosomal LocationXp11.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of HSD17B10. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolHSD17B10
Namehydroxysteroid (17-beta) dehydrogenase 10
Aliases ERAB; MHBD; 17b-HSD10; ABAD; SDR5C1; MRPP2; CAMR; type 10 17b-HSD; type 10 17beta-hydroxysteroid dehydrogena ......
Chromosomal LocationXp11.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of HSD17B10 expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolHSD17B10
Namehydroxysteroid (17-beta) dehydrogenase 10
Aliases ERAB; MHBD; 17b-HSD10; ABAD; SDR5C1; MRPP2; CAMR; type 10 17b-HSD; type 10 17beta-hydroxysteroid dehydrogena ......
Chromosomal LocationXp11.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between HSD17B10 and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolHSD17B10
Namehydroxysteroid (17-beta) dehydrogenase 10
Aliases ERAB; MHBD; 17b-HSD10; ABAD; SDR5C1; MRPP2; CAMR; type 10 17b-HSD; type 10 17beta-hydroxysteroid dehydrogena ......
Chromosomal LocationXp11.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting HSD17B10 collected from DrugBank database.
> Drugs from DrugBank database
 

  Details on drugs targeting HSD17B10.
ID Name Drug Type Targets #Targets
DB00157NADHSmall MoleculeAASS, ACADS, ADH1A, ADH1B, ADH1C, ADH4, ADH5, ADH7, AKR1B1, AKR1C1 ......144
DB028201-Azepan-1-Yl-2-Phenyl-2-(4-Thioxo-1,4-Dihydro-Pyrazolo[3,4-D]Pyrimidin-5-Yl)Ethanone AdductSmall MoleculeHSD17B101